UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor‐induced hypercoagulability in vitro and in vivo

Journal of thrombosis and haemostasis, 2014-07, Vol.12 (7), p.1054-1065

2014

Volltextzugriff (PDF)

In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor

Journal of thrombosis and haemostasis, 2005-03, Vol.3 (3), p.514-521

2005

Volltextzugriff (PDF)

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban

Journal of thrombosis and haemostasis, 2007-04, Vol.5 (4), p.886-888

2007

Volltextzugriff (PDF)

Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis

Journal of thrombosis and haemostasis, 2012-12, Vol.10 (12), p.2470-2480

2012

Volltextzugriff (PDF)

Factor Xa inhibitors--new anticoagulants for secondary haemostasis

Hämostaseologie, 2009, Vol.29 (3), p.260-267

Perzborn, E

2009

Volltextzugriff (PDF)

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor

Thrombosis and haemostasis, 2010-04, Vol.103 (4), p.815-825

2010

Volltextzugriff (PDF)

Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls

Thrombosis and haemostasis, 2012-02, Vol.107 (2), p.379-387

2012

Volltextzugriff (PDF)

Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor

Journal of medicinal chemistry, 2005-09, Vol.48 (19), p.5900-5908

2005

Volltextzugriff (PDF)

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

Thrombosis and haemostasis, 2010-11, Vol.104 (5), p.1078-1079

2010

Volltextzugriff (PDF)

Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin

Thrombosis and haemostasis, 2012-07, Vol.108 (1), p.191-198

2012

Volltextzugriff (PDF)

Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor

Seminars in thrombosis and hemostasis, 2007-07, Vol.33 (5), p.515-523

2007

Volltextzugriff (PDF)

Evaluation of the antifactor XA chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls

European journal of hospital pharmacy. Science and practice, 2012-04, Vol.19 (2), p.236-237

2012

Volltextzugriff (PDF)

Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls

European journal of hospital pharmacy. Science and practice, 2012-04, Vol.19 (2), p.236-236

2012

Volltextzugriff (PDF)

NO-independent regulatory site on soluble guanylate cyclase

Nature (London), 2001-03, Vol.410 (6825), p.212-215

2001

Volltextzugriff (PDF)

Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders

Hämostaseologie, 2007-09, Vol.27 (4), p.282

2007

Volltextzugriff (PDF)

NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

British journal of pharmacology, 2002-07, Vol.136 (5), p.773-783

2002

Volltextzugriff (PDF)

Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies

British journal of pharmacology, 2002-01, Vol.135 (2), p.344-355

2002

Volltextzugriff (PDF)

Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studies

British journal of pharmacology, 2002-01, Vol.135 (2), p.333-343

2002

Volltextzugriff (PDF)

Reduzierter rechtsventrikulärer Druckanstieg und Hypertrophie mit dem oralen, direkten Faktor-Xa-Inhibitor Rivaroxaban in experimenteller pulmonal-arterieller Hypertonie

Pneumologie (Stuttgart, Germany), 2010-01, Vol.64 (S 01), p.S20-S21

2010

Volltextzugriff (PDF)

Rivaroxaban: A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders

Hämostaseologie, 2007, Vol.27 (4), p.282-289

2007

Volltextzugriff (PDF)

COMBINING RIVAROXABAN WITH ACETYLSALICYLIC ACID INCREASES ANTITHROMBOTIC POTENCY WITHOUT AFFECTING BLEEDING TIMES IN ANIMAL MODELS

Journal of thrombosis and haemostasis, 2007-07, Vol.5, p.P-W-639-P-W-639

2007

Volltextzugriff (PDF)

BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics

The Journal of pharmacology and experimental therapeutics, 1993-10, Vol.267 (1), p.51

1993

Volltextzugriff (PDF)

Effect of BAY U 3405, a new thromboxane antagonist, on arachidonic acid induced thromboembolism

Advances in prostaglandin, thromboxane, and leukotriene research, 1991, Vol.21A, p.355

1991

Volltextzugriff (PDF)

Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes

Biochemical pharmacology, 1992-08, Vol.44 (3), p.495-503

1992

Volltextzugriff (PDF)

Nimodipine inhibits carbocyclic thromboxane-induced contractions of cerebral arteries

European journal of pharmacology, 1981-01, Vol.69 (2), p.213-215

1981

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(49)

Sprache

Englisch
(47)
Japanisch
(10)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor‐induced hypercoagulability in vitro and in vivo

In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban

Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis

Factor Xa inhibitors--new anticoagulants for secondary haemostasis

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor

Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls

Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin

Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor

Evaluation of the antifactor XA chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls

Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls

NO-independent regulatory site on soluble guanylate cyclase

Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders

NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies

Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studies

Reduzierter rechtsventrikulärer Druckanstieg und Hypertrophie mit dem oralen, direkten Faktor-Xa-Inhibitor Rivaroxaban in experimenteller pulmonal-arterieller Hypertonie

Rivaroxaban: A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders

COMBINING RIVAROXABAN WITH ACETYLSALICYLIC ACID INCREASES ANTITHROMBOTIC POTENCY WITHOUT AFFECTING BLEEDING TIMES IN ANIMAL MODELS

BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics

Effect of BAY U 3405, a new thromboxane antagonist, on arachidonic acid induced thromboembolism

Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes

Nimodipine inhibits carbocyclic thromboxane-induced contractions of cerebral arteries

Suchergebnisse filtern